Childhood cancers: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 98
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• NF1 12
• ABL1 2
• HER2 25
• PI3K 5
• AKT 1
• CDK4/6 7
• PD-L1 13
• NTRK 10
• NMDA 0
• B7-H3 15
• mTOR 2
• RB1 1
• KMT2A 12
• PSMA 20
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• RAS 1
• CD38 5
• EZH2 0
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

24 of 29+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

  NCT05521087· Janssen Research & Development, LLC· Updated 22 Jun 2025

  “Business Decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

  NCT04811560· Janssen Research & Development, LLC· Source

• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  NCT06317662· National Cancer Institute (NCI)· Source

• A Study of Revumenib and Mezigdomide in People With Leukemia

  NCT07356154· Memorial Sloan Kettering Cancer Center· Source

• Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· Princess Maxima Center for Pediatric Oncology· Source

• Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

  NCT07355335· Massachusetts General Hospital· Source

• A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

  NCT05453903· Janssen Research & Development, LLC· Source

• A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

  NCT05521087· Janssen Research & Development, LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 125
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 31
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 87
• Immunohistochemistry 197
• Liquid Biopsy 25
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 520
• Machine Learning 67
• Deep Learning 25
• Cohort Studies 328
• Genome-Wide Association Study 22

• Integrative Multi-Omics and Single-Cell Analyses Identify FKBP10 as a CAF-Associated Biomarker Linked to ECM Remodeling and Aggressiveness in Neuroblastoma.

  Oncol Res, Oct 2026

• Characterization of chemoresistant cell populations improves risk stratification and therapy prediction in pediatric acute myeloid leukemia.

  Nat Commun, Oct 2026

• Spatial and single-cell dissection of medulloblastoma identifies developmental hierarchies and a prognostic PPIA-BSG tumor-immune axis.

  J Transl Med, Sept 2026

• Integration of Bulk RNA Sequencing and Single-Cell Sequencing to Identify Prognostic Genes Associated With MCDRGs in Neuroblastoma.

  FASEB J, Aug 2026

• Case Report: Single-cell transcriptomic profiling of a pediatric ALK-negative gastric inflammatory myofibroblastic tumor.

  Front Immunol, Aug 2026

• Single-cell chromatin profiling reveals relapse-related priming in pediatric acute myeloid leukemia.

  Life Sci Alliance, Aug 2026

• Ferroptosis-Based Peripheral Immune Dysregulation and Diagnostic Signatures in Parkinson's Disease: An RNA Transcriptomic and Single-Cell Immune Sequencing Analysis.

  FASEB J, Aug 2026

• Improved Surfactant-Assisted One-Pot Sample Preparation for Robust Convenient Single-Cell Proteomics.

  J Proteome Res, Aug 2026

• Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma.

  Sci Adv, Jul 2026

• Single‑cell atlas reveals a Wilms' tumor 1‑mediated axis driving granulosa cell senescence in human ovarian aging.

  Int J Mol Med, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.